Influenza Burden Assessment in the United States, July1997 - up to April 2009
NCT01599390 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 1
Last updated 2013-02-25
Summary
The study will assess the burden of severe influenza outcomes by age, risk status, and influenza subtype, in order to create a profile of the burden of influenza-related morbidity and mortality in United States from July 1997 to April 2009.
Conditions
Interventions
- OTHER
-
Data collection
The study will use multiple primary data sources: the Nationwide Inpatient Sample (for hospitalisations) and the US National Vital Statistics System (for mortality), and weekly virology data from the Centers for Disease Control and Prevention (CDC) influenza surveillance program supplemented with literature data. Weekly time series of the rates of various severe influenza-related health outcomes will be constructed. Statistical models, guided by weekly numbers of cases of laboratory-confirmed influenza and respiratory syncytial virus (RSV) contained in the CDC virology data, will be constructed to estimate the portions of the various outcomes that can be attributed to influenza. Next, the seasonal impact of influenza by age, risk status, and influenza subtype will be assessed. Finally, the potential burden that a quadrivalent vaccine could have prevented over the 12 year study period will be predicted.
Sponsors & Collaborators
-
Sage Analytica
collaborator INDUSTRY - lead INDUSTRY
Principal Investigators
-
GSK Clinical Trials · GlaxoSmithKline
Eligibility
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2012-07-31
- Primary Completion
- 2013-02-28
- Completion
- 2013-02-28
More Related Trials
-
Safety and Immunogenicity of a Commercially Available Influenza Vaccine (Formulation 2007/2008) When Administered to NON Elderly AND Elderly Subjects
NCT00518726 ·Status: COMPLETED ·Phase: PHASE2
-
Influenza in People With Normal and Weakened Immune Systems
NCT00533182 ·Status: COMPLETED
-
Study to Evaluate the Immunogenicity and Safety of an Investigational Influenza Vaccine for the Elderly
NCT00938392 ·Status: COMPLETED ·Phase: PHASE3
-
Safety and Immunogenicity of a Commercially Available Influenza Vaccine (Formulation 2006/2007) When Administered to Subjects 18 Years of Age or Older
NCT00329966 ·Status: COMPLETED ·Phase: PHASE2
-
A Prospective Epidemiological Cohort Study Evaluating Occurrences of Influenza-like Illness.
NCT05184387 ·Status: COMPLETED
-
Safety and Immunogenicity of Surface Antigen, Inactivated, Influenza Vaccine Using the Strain Composition 2009/2010 Recommended in Northern Hemisphere in Non-elderly Adult and in Elderly Subjects
NCT00918268 ·Status: COMPLETED ·Phase: PHASE2
-
Safety and Immunogenicity of a Commercially Available Influenza Vaccine (Formulation 2007/2008) When Administered to Elderly Subjects
NCT00522236 ·Status: COMPLETED ·Phase: PHASE2
-
Does Seasonal Influenza Vaccination Affect the Incidence of pH1N1 Influenza?
NCT01001325 ·Status: COMPLETED ·Phase: PHASE3
-
Comparison of Epidemiology and Clinical Outcomes of Influenza A & B Cases in Manitoba, Canada
NCT01683630 ·Status: COMPLETED
-
B-cell Immunity to Influenza (SLVP017)- Year 1, 2009
NCT02133781 ·Status: COMPLETED ·Phase: PHASE4
-
Dose, Safety, and Pathogenicity of a New Influenza B Strain
NCT06254820 ·Status: RECRUITING ·Phase: PHASE2
-
Safety and Immunogenicity of a Commercially Available Influenza Vaccine (Formulation 2006/2007) When Administered to Subjects 18 Years of Age or Older
NCT00342940 ·Status: WITHDRAWN ·Phase: PHASE2
-
Immunogenicity & Safety Study of Fluviral® (2009 - 2010 Season) in Adults Aged 18 to 60 Years and Over 60 Years
NCT00929331 ·Status: COMPLETED ·Phase: PHASE3
-
Evaluation of Human Immune Responses to Influenza Virus Vaccination in Healthy Volunteers
NCT02385123 ·Status: TERMINATED ·Phase: PHASE4
-
Persistence of Immune Response After Vaccination With Influenza Vaccine
NCT01906190 ·Status: COMPLETED ·Phase: NA
-
Immunogenicity and Safety Study of an Investigational Influenza (H1N1 Influenza Virus) Vaccine in Adults
NCT00989287 ·Status: COMPLETED ·Phase: PHASE3
-
Safety and Immunogenicity of Influenza Vaccine (Surface Antigen, Inactivated) Ph.Eur, Formulation 2008-2009, When Administered to Non-Elderly Adult and Elderly Subjects
NCT00748150 ·Status: COMPLETED ·Phase: PHASE2
-
Influenza Vaccination Among the Elderly Individuals
NCT02362919 ·Status: COMPLETED
-
Dose, Safety, and Pathogenicity of a New Influenza H1N1 Challenge Strain
NCT05572450 ·Status: COMPLETED ·Phase: NA
-
Safety and Immunogenicity of a Commercially Available Influenza Vaccine (Formulation 2006/2007) When Administered to Elderly Subjects
NCT00329927 ·Status: COMPLETED ·Phase: PHASE2
-
Safety and Immunogenicity of the 2005-2006 Fluzone® Vaccine
NCT00258830 ·Status: COMPLETED ·Phase: PHASE4
-
Evaluating Modes of Influenza Transmission Observational Study of Community Acquired Influenza
NCT01769430 ·Status: COMPLETED
-
Pilot Study of Genotypic Analysis
NCT00421837 ·Status: COMPLETED
-
Dose, Safety, and Pathogenicity of a New Influenza A H3N2 Challenge Strain
NCT06613737 ·Status: COMPLETED ·Phase: NA
-
Immunogenicity of a Surface Antigen, Inactivated Influenza Vaccine Formulation 2007-2008
NCT00518453 ·Status: COMPLETED ·Phase: PHASE2